Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
97.15 EUR | +2.91% | +1.57% | -3.43% |
May. 29 | BioMérieux: head injury test cleared by the FDA | CF |
May. 28 | BioMérieux: FDA clearance for Vidas TBI test | CF |
Sales 2024 * | 3.9B 4.23B | Sales 2025 * | 4.19B 4.55B | Capitalization | 11.48B 12.45B |
---|---|---|---|---|---|
Net income 2024 * | 468M 508M | Net income 2025 * | 529M 574M | EV / Sales 2024 * | 2.88 x |
Net cash position 2024 * | 264M 287M | Net cash position 2025 * | 447M 485M | EV / Sales 2025 * | 2.63 x |
P/E ratio 2024 * |
25.1
x | P/E ratio 2025 * |
22.2
x | Employees | 13,696 |
Yield 2024 * |
0.89% | Yield 2025 * |
1.03% | Free-Float | 36.23% |
Latest transcript on bioMérieux
1 day | +2.91% | ||
1 week | +2.59% | ||
Current month | -2.85% | ||
1 month | -2.85% | ||
3 months | -5.31% | ||
6 months | -1.63% | ||
Current year | -3.43% |
Managers | Title | Age | Since |
---|---|---|---|
Pierre Boulud
CEO | Chief Executive Officer | 52 | 16-10-31 |
Chairman | 50 | 04-04-15 | |
Director of Finance/CFO | 47 | 18-02-28 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 74 | 06-09-14 | |
Director/Board Member | 63 | 04-12-31 | |
Chairman | 50 | 04-04-15 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.97% | 14 M€ | -5.07% | ||
0.26% | 1,083 M€ | +4.80% | ||
0.24% | 5 M€ | +4.56% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 97.15 | +2.91% | 690,760 |
24-05-30 | 94.4 | +0.69% | 95,625 |
24-05-29 | 93.75 | -0.42% | 96,516 |
24-05-28 | 94.15 | -1.00% | 82,308 |
24-05-27 | 95.1 | -0.58% | 86,737 |
Real-time Euronext Paris, May 31, 2024 at 11:35 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-3.43% | 12.1B | |
-3.17% | 8.24B | |
+31.98% | 5.58B | |
-10.03% | 4.15B | |
-59.94% | 2.68B | |
+11.23% | 2.63B | |
-5.14% | 2.24B | |
+18.91% | 2.03B | |
-7.56% | 1.79B | |
+3.07% | 1.56B |
- Stock Market
- Equities
- BIM Stock